VOR Phase III MG enrollment complete; key readout eyed for early 2027
VOR says enrollment in its Phase III MG trial is complete, with a key readout expected in early 2027. The company also plans an ocular MG study and enhanced dosing convenience.
Enrollment in the phase III MG trial is complete, and a key readout is expected in early 2027. Telitacicept is described as showing robust efficacy and durability, with plans for an ocular MG study and enhanced dosing convenience. Breadth of response and flexible administration are expected to drive differentiation.